Sartorius earns silver in EcoVadis CSR rating
The company’s engagement in Corporate Social Responsibility includes reducing consumption of water in manufacturing by using innovative technologies.
Sartorius has been awarded for its responsible activities in the areas of environment, labour practices, ethics and sustainable procurement. The company’s engagement in Corporate Social Responsibility (CSR) ranges from supporting the United Nations Global Compact to reducing consumption of water in manufacturing by using innovative technologies, for example, to holding comprehensive employee training courses on work safety. By earning the silver recognition level in the EcoVadis CSR rating platform, Sartorius has positioned itself among the best 30% of the companies assessed.
Companies are increasingly expected to take responsibility not only for their own business activities but also for sustainable supply chain management. EcoVadis operates a platform that provides CSR ratings for global supply chains. The methodology EcoVadis uses in its assessment is based on international CSR standards, such as the international Global Reporting Initiative, the United Nations Global Compact and the ISO 26000 Standard providing guidance on social responsibility. The analytical system covers 21 sustainability criteria for the environment, social aspects, ethics and sustainable procurement. More than 45,000 companies in over 150 countries use EcoVadis. The objective is to create transparency and trust in customer-supplier relationships. EcoVadis assessment is also designed to help drive continuous improvement and minimize the risks of non-compliance with labour and environmental standards.
Sustainability is gaining growing importance worldwide. Customers and investors are increasingly interested in receiving information on environmental practices, business ethics and corporate governance. The silver recognition level confirms the importance that Sartorius attaches to long-term-focused, responsible activities with regard to natural resources, as well as to business partners and staff. As Sartorius moved up in its ranking from bronze to silver, this underlines the company’s progress in the area of CSR.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.